AbCellera Biologics (ABCL) Equity Average (2020 - 2026)

AbCellera Biologics has reported Equity Average for 7 years, with the latest figure at $952.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 8.37% year-over-year to $952.5 million; the trailing twelve-month figure through Mar 2026 stood at $952.5 million (down 8.37% YoY), and the FY2025 full-year result was $1.0 billion, down 8.4% from the prior year.
• Equity Average for Q1 2026 stood at $952.5 million, down from $965.5 million in the prior quarter.
• The five-year high for Equity Average was $1.2 billion in Q4 2022, with the low at $952.5 million in Q1 2026.
• Historically, Equity Average has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• Annual changes were most pronounced in 2022 — Equity Average increased 28.21% — and 2025, when it decreased 9.96%.
• AbCellera Biologics' Equity Average stood at $1.2 billion in 2022, then fell by 5.97% to $1.2 billion in 2023, then decreased by 8.6% to $1.1 billion in 2024, then fell by 9.52% to $965.5 million in 2025, then retreated by 1.34% to $952.5 million in 2026.
• The last three Equity Average figures came in at $952.5 million (Q1 2026), $965.5 million (Q4 2025), and $985.6 million (Q3 2025), per Business Quant data.